• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara to launch version 8.0 of D360 big data platform

Certara to launch version 8.0 of D360 big data platform

February 18, 2015
CenterWatch Staff

Certara, a global biosimulation technology-enabled drug development and drug safety consulting company, will be launching version 8.0 of its D360 R&D big data platform for the biopharmaceutical industry.

Certara’s D360 R&D data platform solves big data challenges faced by scientists and IT staff throughout biopharmaceutical organizations by integrating and leveraging the large amount of diverse scientific data generated by sponsor companies and their outsourced partners to optimize crucial R&D decisions.

“D360 breaks down barriers between R&D siloes, giving executives access to the entire discovery, preclinical and clinical data collection when they need to make the crucially-important go/no-go decision on new drug candidates,” said Gavin Nichols, Certara’s president of technology and head of its software business unit. “By allowing development teams to leverage existing research fully, D360 has enabled our clients to optimize compound development to achieve specific parameters, improve safety profiles of promising candidates, guide future studies based on scientific and statistical data, and anticipate regulatory questions. In addition, D360 provides the C-suite with a flexible solution which can be easily scaled to fit new outsourcing business models.”

Nichols said, “By providing an end-to-end solution, D360 reduces the ongoing costs and time required to manage heterogeneous data platforms for the organization’s IT team. D360 also empowers scientific users by increasing the speed with which they can access information and making it easier for them to collaborate with other scientists.”   

D360 provides scientific data integration, access, analysis and visualization capabilities for early discovery through to the preclinical and clinical phases of drug development. D360 solves both intra and inter-domain research challenges by integrating data from multiple source systems to provide standard data views and data mining capabilities. In addition, D360 brings context and understanding to the data, enabling scientists to gain deeper insight and make better scientific decisions.

D360 v8.0 builds on the platform’s base capabilities and includes connections to broader and more diverse data sets; new tools for collaboration within an organization and across external partners; and improved performance and usability, providing faster time to insight.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing